Canaccord Genuity reaffirmed their buy rating on shares of Harpoon Therapeutics (NASDAQ:HARP) in a report released on Monday, AnalystRatings.com reports. They currently have a $30.00 price target on the stock.

Several other research analysts have also recently commented on HARP. Citigroup boosted their price target on Harpoon Therapeutics from $24.00 to $25.00 and gave the stock a buy rating in a research note on Monday, August 10th. Zacks Investment Research cut Harpoon Therapeutics from a buy rating to a hold rating in a research note on Tuesday, August 4th. HC Wainwright reiterated a buy rating on shares of Harpoon Therapeutics in a research note on Monday, June 1st. Piper Sandler began coverage on Harpoon Therapeutics in a research note on Friday, May 22nd. They issued an overweight rating and a $35.00 price target on the stock. Finally, BidaskClub cut Harpoon Therapeutics from a sell rating to a strong sell rating in a research note on Friday, July 24th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. Harpoon Therapeutics presently has an average rating of Buy and a consensus price target of $29.50.

Shares of HARP opened at $16.42 on Monday. The stock’s 50-day moving average is $13.29 and its two-hundred day moving average is $14.56. The stock has a market cap of $412.83 million, a PE ratio of -7.30 and a beta of 1.11. Harpoon Therapeutics has a 12 month low of $10.27 and a 12 month high of $25.02. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.48 and a quick ratio of 4.48.

Harpoon Therapeutics (NASDAQ:HARP) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.04). Harpoon Therapeutics had a negative return on equity of 62.20% and a negative net margin of 571.20%. On average, research analysts anticipate that Harpoon Therapeutics will post -2.11 earnings per share for the current year.

In related news, insider Holger Wesche sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $16.20, for a total value of $162,000.00. Following the completion of the sale, the insider now directly owns 62,669 shares of the company’s stock, valued at $1,015,237.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 34.90% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA grew its holdings in shares of Harpoon Therapeutics by 55.7% during the first quarter. BNP Paribas Arbitrage SA now owns 2,272 shares of the company’s stock valued at $26,000 after purchasing an additional 813 shares during the last quarter. Public Employees Retirement System of Ohio grew its holdings in shares of Harpoon Therapeutics by 97.4% during the second quarter. Public Employees Retirement System of Ohio now owns 3,290 shares of the company’s stock valued at $55,000 after purchasing an additional 1,623 shares during the last quarter. American International Group Inc. grew its holdings in shares of Harpoon Therapeutics by 49.0% during the second quarter. American International Group Inc. now owns 6,467 shares of the company’s stock valued at $107,000 after purchasing an additional 2,126 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Harpoon Therapeutics during the first quarter valued at approximately $90,000. Finally, Engineers Gate Manager LP bought a new position in shares of Harpoon Therapeutics during the second quarter valued at approximately $166,000. 80.39% of the stock is owned by institutional investors.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Featured Article: Inverted Yield Curve

Analyst Recommendations for Harpoon Therapeutics (NASDAQ:HARP)

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.